Both cladribine and alemtuzumab may effect MS via B-cell depletion

OBJECTIVE: To understand the efficacy of cladribine (CLAD) treatment in MS through analysis of lymphocyte subsets collected, but not reported, in the pivotal phase III trials of cladribine and alemtuzumab induction therapies. METHODS: The regulatory submissions of the CLAD Tablets Treating Multiple...

Descripción completa

Detalles Bibliográficos
Autores principales: Baker, David, Herrod, Samuel S., Alvarez-Gonzalez, Cesar, Zalewski, Lukasz, Albor, Christo, Schmierer, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459792/
https://www.ncbi.nlm.nih.gov/pubmed/28626781
http://dx.doi.org/10.1212/NXI.0000000000000360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459792/
https://www.ncbi.nlm.nih.gov/pubmed/28626781
http://dx.doi.org/10.1212/NXI.0000000000000360

Ejemplares similares